HelioLiver: Expanding Early Detection of Hepatocellular Carcinoma With AI

About this episode

The episode discusses the potential of HelioLiver, an AI-powered blood test, in the early detection of hepatocellular carcinoma.

Read the full article at: https://oncdata.com/exploring-ai-helioliver Patients diagnosed with early-stage liver cancer have a significantly higher survival rate compared to those diagnosed in later stages, yet screening options and barriers persist. In the latest episode of Exploring AI in Oncology, Waqas Haque, MD, MPH, speaks with Bharat Tewarie, MD, MBA, the CEO of Helio Genomics, about the company’s AI-powered blood test, HelioLiver, and its potential role in detecting hepatocellular carcinoma (HCC), the most common form of liver cancer. Dr. Tewarie shares why liver cancer is a strong use case for blood-based early detection, how HelioLiver may fit into existing workflows, and barriers to overcome for broader adoption.

People in this episode

Host: Waqas Haque, MD, MPH

Guest: Bharat Tewarie, MD, MBA

Topics covered

• early detection
• liver cancer
• AI in oncology
• blood tests
• healthcare barriers

Keywords

• liver cancer
• early detection
• AI
• blood test
• HCC
• HelioLiver
• oncology

Mentioned in this episode

Organizations: Helio Genomics

Products: HelioLiver

Places: Hepatocellular Carcinoma

More episodes of Oncology Data Advisor

• Multidisciplinary Realities: Tumor Board vs Tuesday Afternoon · May 29, 2026 · 20 min
• The Real World vs The Trial Patient: Bridging the Gap · May 11, 2026 · 20 min
• AI-Driven Pathological Subtyping for Pancreatic Cancer: Moving From Promise to Practical Application · May 4, 2026 · 14 min
• Solving the PFIC Mystery: Genetic Testing and Diagnosis in Adults · April 30, 2026 · 14 min
• New Frontiers in Esophagogastric Cancer with Dr. Yelena Janjigian · April 8, 2026 · 8 min
• HER2-Mutant NSCLC Update: Expanded Approval of Zongertinib · April 3, 2026 · 6 min